SOLIGENIX, INC. Files S-1/A Amendment

TL;DR

<b>SOLIGENIX, INC. (SNGX) has filed an S-1/A amendment detailing corporate actions and financial instrument events.</b>

AI Summary

SOLIGENIX, INC. (SNGX) filed a Amended IPO Registration (S-1/A) with the SEC on April 2, 2024. SOLIGENIX, INC. filed an S-1/A amendment on April 2, 2024. The company was formerly known as DOR BIOPHARMA INC, ENDOREX CORP, and IMMUNOTHERAPEUTICS INC. Key dates include a public offering of common stock on May 9, 2023, and an exclusive option agreement on May 2, 2023. Subsequent events include convertible debt on January 3, 2024. The filing references Series D Preferred Stock and Common Stock transactions throughout 2022 and 2023.

Why It Matters

For investors and stakeholders tracking SOLIGENIX, INC., this filing contains several important signals. The S-1/A filing provides an updated view of the company's financial structure and recent corporate activities, including stock offerings and agreements. This amendment is crucial for investors to understand the latest developments in SOLIGENIX's capital structure and potential future equity issuances.

Risk Assessment

Risk Level: — SOLIGENIX, INC. shows moderate risk based on this filing. The filing is an amendment (S-1/A) which typically updates previous filings rather than introducing entirely new, high-risk information. Specific financial figures and dates are provided, indicating a structured update.

Analyst Insight

Review the specific details of the convertible debt issuance on January 3, 2024, and the common stock transactions in 2023 to assess their impact on dilution and capital structure.

Key Numbers

• 2024-04-02 — Filing Date (S-1/A filing date)
• 2023-12-31 — Fiscal Year End (Company fiscal year end)
• 2023-05-09 — Public Offering Date (Common Stock Public Offering)
• 2024-01-03 — Convertible Debt Date (Subsequent Event - Convertible Debt)

Key Players & Entities

• SOLIGENIX, INC. (company) — FILER
• DOR BIOPHARMA INC (company) — FORMER COMPANY
• ENDOREX CORP (company) — FORMER COMPANY
• IMMUNOTHERAPEUTICS INC (company) — FORMER COMPANY
• 2024-04-02 (date) — FILED AS OF DATE
• 2023-05-09 (date) — PublicOfferingMember
• 2023-05-02 (date) — ExclusiveOptionAgreementMember
• 2024-01-03 (date) — SubsequentEventMember

FAQ

Industry Context

SOLIGENIX, INC. operates in the Pharmaceutical Preparations industry. This S-1/A filing provides updates relevant to its financial and corporate structure.

Regulatory Implications

The filing is an S-1/A, an amendment to a registration statement, indicating ongoing compliance and disclosure requirements under the Securities Act of 1933.

What Investors Should Do

1. Review the terms and implications of the January 3, 2024 convertible debt issuance.
2. Analyze the impact of the May 9, 2023, public offering on share count and dilution.
3. Investigate the details and potential outcomes of the exclusive option agreement dated May 2, 2023.

Key Dates

• 2024-04-02: S-1/A Filing — Updated corporate and financial information
• 2024-01-03: Convertible Debt Issuance — Subsequent event impacting debt structure
• 2023-05-09: Common Stock Public Offering — Equity financing event
• 2023-05-02: Exclusive Option Agreement — Strategic agreement

Year-Over-Year Comparison

This S-1/A filing updates previous disclosures with specific dates for stock offerings, agreements, and subsequent events, providing a more current snapshot of the company's financial activities.

Key Financial Figures

• $10.0 million — Common Warrants We are offering up to $10.0 million of shares of common stock together with
• $0.61 — have assumed a public offering price of $0.61 per share, the last reported sale price
• $0.001 — mmon stock and has an exercise price of $0.001 per share. Each pre-funded warrant is b
• $1.00 — maintain a minimum closing bid price of $1.00 for 30 consecutive trading days. In acc
• $5,000,000 m — riod because we did not comply with the $5,000,000 minimum stockholders' equity initial list
• $4,221,155 — , 2023 reported stockholders' equity of $4,221,155. As a result, the notice indicated that
• $2,522,422 — 23, we reported stockholders' equity of $2,522,422. There can be no assurance that we will
• $6,419,907 — securities and publicly held shares was $6,419,907 and $6,413,449, respectively. As of Dec
• $6,413,449 — publicly held shares was $6,419,907 and $6,413,449, respectively. As of December 31, 2023,
• $8,446,158 — 23, we had cash and cash equivalents of $8,446,158, working capital of $3,355,212 and tota
• $3,355,212 — lents of $8,446,158, working capital of $3,355,212 and total liabilities of $7,274,904, of
• $7,274,904 — of $3,355,212 and total liabilities of $7,274,904, of which over 44.8% was owed under our
• $250 million — on stock held by non-affiliates exceeds $250 million as of the prior June 30, or (2) our ann
• $100 million — 30, or (2) our annual revenues exceeded $100 million during such completed fiscal year and t
• $700 million — on stock held by non-affiliates exceeds $700 million as of the prior June 30. 2 Table of C

Filing Documents

• sngx-20231231xs1a.htm (S-1/A) — 2776KB
• sngx-20231231xex23d1.htm (EX-23.1) — 5KB
• sngx-20231231xex23d2.htm (EX-23.2) — 5KB
• sngx-20231231xs1a001.jpg (GRAPHIC) — 7KB
• sngx-20231231xs1a009.jpg (GRAPHIC) — 1KB
• sngx-20231231xs1a010.jpg (GRAPHIC) — 1KB
• sngx-20231231xs1a025.jpg (GRAPHIC) — 4KB
• 0001558370-24-004621.txt (&nbsp;) — 9562KB
• sngx-20231231.xsd (EX-101.SCH) — 62KB
• sngx-20231231_cal.xml (EX-101.CAL) — 61KB
• sngx-20231231_def.xml (EX-101.DEF) — 286KB
• sngx-20231231_lab.xml (EX-101.LAB) — 551KB
• sngx-20231231_pre.xml (EX-101.PRE) — 433KB
• sngx-20231231xs1a_htm.xml (XML) — 1402KB

RISK FACTORS

RISK FACTORS 9 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA AND MARKET INFORMATION 31

USE OF PROCEEDS

USE OF PROCEEDS 32 DIVIDEND POLICY 33 MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS 34 CAPITALIZATION 35

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 38

BUSINESS

BUSINESS 47 MANAGEMENT 75

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 80 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 84

SECURITY OWNERSHIP OF MANAGEMENT AND OTHER BENEFICIAL OWNERS

SECURITY OWNERSHIP OF MANAGEMENT AND OTHER BENEFICIAL OWNERS 85

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 87

DESCRIPTION OF SECURITIES WE ARE OFFERING

DESCRIPTION OF SECURITIES WE ARE OFFERING 90 PLAN OF DISTRIBUTION 93 LEGAL MATTERS 95 EXPERTS 96 WHERE YOU CAN FIND MORE INFORMATION 96 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 Neither we nor the Placement Agent have authorized anyone to give any information or to make any representations other than those contained in this prospectus. You must not rely on any information or representations not contained in this prospectus. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date. Table of Contents PROSPECTUS SUMMARY This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information that you should consider before deciding to invest in our securities. You should carefully read this entire prospectus before making an investment decision, including the information presented under the headings " Risk Factors " and " Cautionary Note Regarding Forward-Looking Statements and Industry Data and Market Information " in this prospectus and the historical financial statements and the notes thereto included elsewhere in this prospectus. You should pay special attention to the information contained under the caption titled "Risk Factors" in this prospectus, before deciding to buy our securities. In this prospectus, the terms " Soligenix, " " Soligenix, Inc., " the "Company, " " we, " " our, " " ours " and " us " refer to Soligenix, Inc. and its subsidiaries. Overview We are a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. We maintain two active business segments: Specialized BioTherapeutics and Public Health Solutions. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercial

Use of proceeds

Use of proceeds We estimate that the net proceeds from this offering will be approximately $9,150,000, at an assumed public offering price of $0.61 per share (assuming a public offering price equal to the last sale price of our common stock as reported by The Nasdaq Capital Market on March 27, 2024, which was $0.61 per share), after deducting the Placement Agent fee and estimated offering expenses payable by us. We intend to use the net proceeds from the sale of the securities offered by us pursuant to this prospectus to fund our research and development and commercialization activities, and for general corporate and working capital purposes, which may include, among other things, working capital, product development and/or commercialization, acquisitions, capital expenditures, repayment of debt and other business opportunities. See the section titled " Use of Proceeds " on page 32 of this prospectus.

Risk Factors

Risk Factors See " Risk Factors " and other information appearing elsewhere in this prospectus for a discussion of factors you should carefully consider before deciding whether to invest in our securities. Lock-up We have agreed, subject to certain exceptions and without the approval of the Placement Agent and purchasers of our securities in this offering, not to (1) issue, enter into any agreement to issue or announce the issuance or proposed issuance of, any shares of common stock (or securities convertible into or exercisable for common stock) or file any registration statement, including any amendments or supplements for a period of 90 days following the closing of the offering of the shares and (2) enter into a variable rate transaction for a period of one year following the closing of this offering, other than an " at-the-market " offering following 90 days from the closing of this offering. Our directors and officers have agreed not to offer, sell, pledge or otherwise transfer or dispose of any of our securities for 90 days following the closing of the offering of the shares. See " Plan o

View Full Filing

View this S-1/A filing on SEC EDGAR